Monday, February 16, 2026 2/16/2026

Novel macrophage and regulatory T cell interactions that promote the pathogenesis of Duchenne muscular dystrophy

Award Number: R01NS120060
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2020
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Novel macrophage and regulatory T cell interactions that promote the pathogenesis of Duchenne muscular dystrophy - PROJECT SUMMARY The long-term goal of our research is to determine how the immune system interfaces with cells in the dystrophic niche to impact the pathogenesis of Duchenne muscular dystrophy (DMD), to provide a foundation for developing novel treatments for this devastating disease. The objective of the current study is to define how regulatory T cells (Treg) regulate macrophage-stromal interactions in muscle, and how these interactions can be pharmacologically manipulated to alter disease progression. We provide strong scientific premise for proposing the central hypothesis that Tregs regulate the severity of DMD by suppressing a distinct galectin-3+ muscle macrophage population that promotes fibrosis. This hypothesis is supported by our preliminary data and prior research, showing that 1) dystrophic muscle is populated by a putative fibrogenic galectin-3+/Spp1+ macrophage that we identified by single-cell RNA sequencing (scRNAseq); 2) prior research showing that spp1 promotes fibrosis in mdx mice; 3) macrophage-specific deletion of Spp1 in mdx mice causes remarkable changes in the transcriptional profile of PGFRa+ stromal cells, as assessed by scRNAseq; 4) galectin-3+ macrophages are expanded when Tregs are depleted in mdx mice, suggesting that Tregs suppress fibrogenic macrophages and 5) depletion of Tregs in mdx mice causes an increased expression of pro-fibrotic genes. We will test our central hypothesis by addressing two specific aims. Specific aim 1 will define how galectin-3+ muscle macrophages promote fibrosis. Two subaims will be addressed under specific aim 2, identify the molecular basis for Treg suppression of galectin-3+ muscle macrophages. In subaim 2a we will determine whether the Treg-mediated suppression of IFNg-producing cells is IL-10 dependent; and in subaim 2b we will examine whether the therapeutic expansion of Tregs suppresses fibrosis. Although a role for Spp1 in promoting fibrosis in mdx mice has been documented, a mechanism for this pathological process is largely unknown. Thus, our proposed study is significant as it will define the cellular basis by which Spp1 promotes muscle fibrosis, and advance our understanding of how Tregs ameliorate the severity of muscular dystrophy. The proposed research is innovative because it will define mechanisms of cellular cross talk that promote fibrosis in dystrophic muscles. The proposed studies use innovative technologies (e.g. scRNAseq) and experimental therapeutics (e.g. IL-2c) that will provide the framework for developing novel approaches to inhibit the development of fibrosis. These potential discoveries will advance the field by establishing interactions between the lymphoid and myeloid compartment of the immune system that operate in DMD to suppress or limit fibrogenic responses. Further, findings from the proposed studies are expected to have significant clinical implications for DMD, as the immunosuppressive function of Tregs can be therapeutically augmented to ameliorate disease severity by inhibiting pro-fibrotic inflammatory responses.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	8/13/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $417,457 )
2024	2024	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	8/19/2024	NON-COMPETING CONTINUATION	$398,837
2024	2024	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	5	8/21/2024	SUPPLEMENT FOR EXPANSION	$18,620
														Subtotal = $417,457

Issue Date FY: 2023 ( Subtotal = $511,471 )
2023	2023	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	8/21/2023	NON-COMPETING CONTINUATION	$430,215
2023	2023	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	4	8/23/2023	SUPPLEMENT FOR EXPANSION	$81,256
														Subtotal = $511,471

Issue Date FY: 2022 ( Subtotal = $570,377 )
2022	2022	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	002	3	8/31/2022	NON-COMPETING CONTINUATION	$426,485
2022	2022	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	003	3	9/1/2022	SUPPLEMENT FOR EXPANSION	$81,256
2022	2022	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	1/20/2022	SUPPLEMENT FOR EXPANSION	$62,636
2022	2021	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	2	8/31/2022	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $570,377

Issue Date FY: 2021 ( Subtotal = $555,661 )
2021	2021	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	1	8/30/2021	SUPPLEMENT FOR EXPANSION	$18,298
2021	2021	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	8/30/2021	NON-COMPETING CONTINUATION	$422,861
2021	2021	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	003	1	9/7/2021	SUPPLEMENT FOR EXPANSION	$0
2021	2021	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	002	2	9/2/2021	SUPPLEMENT FOR EXPANSION	$114,502
														Subtotal = $555,661

Issue Date FY: 2020 ( Subtotal = $419,346 )
2020	2020	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/21/2020	NEW	$419,346
														Subtotal = $419,346

Grand Total All Awards = $2,474,312

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel macrophage and regulatory T cell interactions that promote the pathogenesis of Duchenne muscular dystrophy

Award Number: R01NS120060

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2020

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer